

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/045,607	10/23/2001	Lino Tavares	208.1004US	1029
75	90 10/01/2004		EXAM	INER
Davidson, Davidson & Kappel, LLC			GHALI, ISIS A D	
14th Floor		-	ART UNIT	PAPER NUMBER
485 Seventh Av New York, NY			1615 DATE MAILED: 10/01/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
·	10/045,607	TAVARES ET AL.				
Advisory Action	Examiner	Art Unit				
	Isis Ghali	1615				
The MAILING DATE of this communication appe			lress			
THE REPLY FILED 09 September 2004 FAILS TO PLA Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (condition for allowance; (2) a timely filed Notice of Appe Examination (RCE) in compliance with 37 CFR 1.114.	ivoid abandonment of this app 1) a timely filed amendment was all (with appeal fee); or (3) a ti	olication. A proper re which places the appli	ply to a cation in			
PERIOD FOR RE	EPLY [check either a) or b)]					
a) The period for reply expiresmonths from the mailing date of the final rejection.						
The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The data have been filed is the date for purposes of determining the period of extension 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three meanned patent term adjustment. See 37 CFR 1.704(b).	ision and the corresponding amount of d statutory period for reply originally se	the fee. The appropriate ex in the final Office action; or	dension fee under r (2) as set forth in			
1. A Notice of Appeal was filed on Appellant 37 CFR 1.192(a), or any extension thereof (37 CF	's Brief must be filed within th R 1.191(d)), to avoid dismiss	e period set forth in all of the appeal.				
2. The proposed amendment(s) will not be entered by	pecause:					
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) they present additional claims without cance	eling a corresponding number	of finally rejected cla	ims.			
NOTE: <u>See Continuation Sheet.</u> 3. Applicant's reply has overcome the following reje						
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	d be allowable if submitted in	a separate, timely file	ed amendment			
5. The a) affidavit, b) exhibit, or c) request for application in condition for allowance because:		onsidered but does N	IOT place the			
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	ecause it is not directed SOLE	LY to issues which w	ere newly			
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims v	nt(s) a)⊠ will not be entered o would be rejected is provided	or b)  will be entered below or appended.	d and an			
The status of the claim(s) is (or will be) as follows	S:					
Claim(s) allowed:						
Claim(s) allowed Claim(s) objected to: <u>1, 2, 4-11, 13-16, 20-24, 26, 27, 29-38, 40-45</u> .						
Claim(s) rejected: <u>39</u> .						
Claim(s) withdrawn from consideration:						
8. The drawing correction filed on is a) ap	proved or b) disapproved	by the Examiner.				
9. Note the attached Information Disclosure Statem						

ontinuation of 2. NOTE:

he release rate and plasma conc. are controlled by the composition and structure of the transdermal device, which are taught by the mbined teaching of the prior art, and it is expected from a transdermal device having the same structure and composition to provide a same delivery profile and plasma level. The withdrawn claim has not been addressed in the present applicant's response.

SUPERVISORY PATENT EXAMINER